Corticosteroid Dosing and Glucose Levels in COPD Patients Are Not Associated with Increased Readmissions

被引:3
作者
McGraw, Meghan [1 ]
White, Heath D. [1 ]
Zolfaghari, Kiumars [1 ]
Hochhalter, Angela [1 ]
Arroliga, Alejandro [1 ]
Boethel, Carl [1 ]
机构
[1] Baylor Scott & White Hlth, Div Pulm Crit Care & Sleep Med, Temple, TX USA
关键词
COPD; chronic obstructive pulmonary disease; readmission; corticosteroid dosing; hyperglycemia; GLUCOCORTICOID THERAPY; EXACERBATIONS; RISK; HYPERGLYCEMIA; DISEASE;
D O I
10.15326/jcopdf.2020.0172
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Hospital admissions and readmissions for chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased mortality and higher cost. The management of exacerbations with a shortened course of systemic corticosteroids has similar efficacy as compared to longer steroid courses, but actual overall steroid dose given is still variable. The outcomes associated with steroid side effects, such as hyperglycemia, need further evaluation. We hypothesized that the use of higher doses of corticosteroids, and the subsequent hyperglycemia, contributes to readmission. Methods: This is a retrospective study at a tertiary care referral center in central Texas between February 2014 and July 2016. Daily corticosteroid dose, blood glucose levels, and readmission rates at 30 and 31-90 days were recorded. Sample characteristics are described using descriptive statistics. A chi-square test or student's t-test were used to test for associations in bivariate comparisons. Multivariable logistic regression assessed the association between readmission rate and demographic and clinical characteristics. Results: There were 1120 patients admitted for COPD exacerbation between February 2014 and July 2016. A total of 57% were female, mean age was 69 years (standard deviation [SD] 12), and average body mass index (BMI) was 29.4 (SD 9.8). Of the total, 349 (31%) had diabetes prior to admission. The 30-day readmission rate was 16 degrees A4 and the readmission rate from 31 90 days was 14% The average prednisone equivalent dose per day during hospitalization was 86 mg (SD 52). A multivariable logistic regression model did not show any significant association between readmission and average daily glucose, high maximum glucose (>180mg/dL on any reading), or prednisone equivalent administered per day. Conclusion: Corticosteroid dose and hyperglycemia were not associated with an increased 30-day or 31-90-day readmission rate after COPD exacerbation discharge. In addition, using higher doses of corticosteroids instead of standard-of-care (prednisone 40mg per day for a 5-day period) did not appear to affect the readmission rate in this cohort.
引用
收藏
页码:117 / 123
页数:7
相关论文
共 11 条
[1]   Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD The EPOC en Servicios de Medicina Interna (ESMI) Study [J].
Almagro, Pedro ;
Javier Cabrera, Francisco ;
Diez, Jesus ;
Boixeda, Ramon ;
Alonso Ortiz, M. Belen ;
Murio, Cristina ;
Soriano, Joan B. .
CHEST, 2012, 142 (05) :1126-1133
[2]   Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly [J].
Blackburn, D ;
Hux, J ;
Mamdani, M .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (09) :717-720
[3]   Managing diabetes during glucocorticoid therapy - How to avoid metabolic emergencies [J].
Braithwaite, SS ;
Barr, WG ;
Rahman, A ;
Quddusi, S .
POSTGRADUATE MEDICINE, 1998, 104 (05) :163-+
[4]   Glucocorticoid-induced hyperglycaemia in respiratory disease: a systematic review and meta-analysis [J].
Breakey, S. ;
Sharp, S. J. ;
Adler, A. I. ;
Challis, B. G. .
DIABETES OBESITY & METABOLISM, 2016, 18 (12) :1274-1278
[5]   To evaluate prescribing practices of corticosteroids in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease (COPD) [J].
Gill, C. M. ;
O'Carroll, O. ;
Collins, O. ;
McGrath, E. ;
Kelly, E. .
IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 :S163-S164
[6]   Association of Corticosteroid Dose and Route of Administration With Risk of Treatment Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease [J].
Lindenauer, Peter K. ;
Pekow, Penelope S. ;
Lahti, Maureen C. ;
Lee, Yoojin ;
Benjamin, Evan M. ;
Rothberg, Michael B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (23) :2359-2367
[7]   A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy [J].
Liu, Dora ;
Ahmet, Alexandra ;
Ward, Leanne ;
Krishnamoorthy, Preetha ;
Mandelcorn, Efrem D. ;
Leigh, Richard ;
Brown, Jacques P. ;
Cohen, Albert ;
Kim, Harold .
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2013, 9
[8]   The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use [J].
Manson, Stephanie C. ;
Brown, Ruth E. ;
Cerulli, Annamaria ;
Vidaurre, Carlos Fernandez .
RESPIRATORY MEDICINE, 2009, 103 (07) :975-994
[9]   Hospitalized Exacerbations of COPD Risk Factors and Outcomes in the ECLIPSE Cohort [J].
Muellerova, Hana ;
Maselli, Diego J. ;
Locantore, Nicholas ;
Vestbo, Jorgen ;
Hurst, John R. ;
Wedzicha, Jadwiga A. ;
Bakke, Per ;
Agusti, Alvar ;
Anzueto, Antonio .
CHEST, 2015, 147 (04) :999-1007
[10]   Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease [J].
Niewoehner, DE ;
Erbland, ML ;
Deupree, RH ;
Collins, D ;
Gross, NJ ;
Light, RW ;
Anderson, P ;
Morgan, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (25) :1941-1947